Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celldex Therapeutics (CLDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 91,483
  • Shares Outstanding, K 143,390
  • Annual Sales, $ 12,740 K
  • Annual Income, $ -93,030 K
  • 36-Month Beta 2.52
  • Price/Sales 7.17
  • Price/Cash Flow N/A
  • Price/Book 0.68
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.73
  • Most Recent Earnings -0.03 on 03/07/18
  • Next Earnings Date 05/08/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.62 +2.44%
on 05/24/18
0.84 -25.00%
on 05/07/18
-0.12 (-15.44%)
since 04/25/18
3-Month
0.62 +2.44%
on 05/24/18
2.86 -77.97%
on 03/09/18
-1.74 (-73.42%)
since 02/23/18
52-Week
0.62 +2.44%
on 05/24/18
3.26 -80.67%
on 10/09/17
-2.47 (-79.68%)
since 05/25/17

Most Recent Stories

More News
Celldex Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that two abstracts will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago....

CLDX : 0.63 (-1.25%)
Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down

Celldex (CLDX) reports wider-than-expected loss in Q1 but sales beat estimates. It discontinues development of its lead pipeline candidate following its failure in breast cancer study.

CLDX : 0.63 (-1.25%)
ENTA : 96.46 (-1.25%)
LLY : 82.77 (+0.07%)
BMY : 52.77 (+0.15%)
Celldex (CLDX) Q1 Loss Narrower, Revenues Beat, Shares Down

Celldex (CLDX) beat earnings and sales estimates in the first quarter.

CLDX : 0.63 (-1.25%)
Celldex Provides Corporate Update and Reports First Quarter 2018 Results

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2018.

CLDX : 0.63 (-1.25%)
What's in Store for Celldex (CLDX) This Earnings Season?

With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on its immuno-oncology pipeline.

CLDX : 0.63 (-1.25%)
ARRY : 15.89 (+1.60%)
APVO : 5.43 (-0.55%)
BMY : 52.77 (+0.15%)
Data from Multiple Celldex Programs Presented at American Association for Cancer Research (AACR) Annual Meeting 2018

-- Early data from investigator-initiated pilot study of CDX-301/radiation therapy combination in patients with advanced NSCLC show promising effect on tumor burden even in non-irradiated tumors --

CLDX : 0.63 (-1.25%)
Analysis: Positioning to Benefit within Celldex Therapeutics, McDermott International, Briggs & Stratton, Tile Shop Hldgs, Essendant, and Anworth Mortgage Asset -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Celldex Therapeutics, Inc....

CLDX : 0.63 (-1.25%)
TTS : 7.35 (-1.34%)
BGG : 18.84 (-0.32%)
ESND : 14.00 (+2.79%)
MDR : 21.57 (-1.51%)
ANH : 5.02 (+0.60%)
Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics

The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.

CLDX : 0.63 (-1.25%)
GILD : 67.38 (-0.22%)
BLCM : 8.00 (-0.37%)
ALKS : 45.77 (+0.77%)
ALXN : 117.74 (+0.51%)
Celldex's Phase II Breast Cancer Study Fails, Shares Plunge

Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.

CLDX : 0.63 (-1.25%)
LLY : 82.77 (+0.07%)
RHHBY : 27.3900 (-0.83%)
BMY : 52.77 (+0.15%)
Today's Research Reports on Stocks to Watch: Celldex Therapeutics and Cancer Genetics

NEW YORK, NY / ACCESSWIRE / April 17, 2018 / Shares of Celldex fell to record lows on Monday after its triple negative breast cancer drug candidate didn't meet endpoints in a phase 2b trial. The company...

CLDX : 0.63 (-1.25%)
CGIX : 1.03 (+5.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CLDX with:

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

2nd Resistance Point 0.66
1st Resistance Point 0.65
Last Price 0.63
1st Support Level 0.62
2nd Support Level 0.60

See More

52-Week High 3.26
Fibonacci 61.8% 2.25
Fibonacci 50% 1.94
Fibonacci 38.2% 1.63
Last Price 0.63
52-Week Low 0.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar